PLOS: DNA Science

APRIL 4, 2024

Among the barrage of drug ads for cancer, diabetes, weight loss and more are those for Lume , a “doctor-developed whole body deodorant.” ” The Patent Trail Rather than relying on social media, company websites, and testimonials, I consulted the Patent and Trademark database to reconstruct the story of invention.

Disease 65

Disease Testimonials Production FDA 65

PLOS: DNA Science

OCTOBER 19, 2023

Remove MSCs from a person with ALS, stimulate them to release the correct brew of neurotrophic factors, then return the doctored cells into the patients spinal fluid, where they should bathe neurons and their supportive glial cells with the nurturing factors.

Therapies 81

Therapies FDA Clinical Trials DNA 81

Drug & Device Law

JULY 24, 2023

3d , 2023 WL 4191651 (C.D. PATDC82 II , 2023 WL 4191651, at *3. 2023 WL 4191651, at *8. PATDC82 II , 2023 WL 4191651, at *10. This time-tested type of evidence is mostly absent from the analysis in PATDC82 II – as in Neurontin , the only actual prescriber testimony belied plaintiffs’ position.

Testimonials 52

Testimonials Pharmacy FDA Doctors 52

Drug & Device Law

DECEMBER 28, 2022

As we prepare to greet 2023, we find ourselves assuming the Janus-ian posture of simultaneously looking backward and forward. Based on that finding, the FDA required new warnings for doctors to consider the risks and benefits of initiating use of the drug with patients facing a higher risk of heart failure.

FDA 59

FDA Science Testimonials Hospitals 59

Drug & Device Law

JUNE 15, 2023

Ladapo , 2023 WL 3833848 (N.D. 2023), appeared in our daily search results because it briefly addresses off-label use of prescription drugs. 2023 WL 3833848, at *3. Doe , 2023 WL 3833848, at *2. 2023 WL 3833848, at *2. 2023 WL 3833848, at *2. 2023 WL 3833848, at *2. The case we discuss today, Doe v.

Doctors 122

Doctors Testimonials Treatment International 122

Drug & Device Law

FEBRUARY 11, 2024

3d , 2023 WL 2825871 (N.D. April 7, 2023) (“ AHM I ”). 2023) (“ AHM II ”). Doctors Who Perform Abortions: Their Characteristics & Patterns of Holding & Using Hospital Privileges,” 6. See AHM I , 2023 WL 2825871, at *4 n.9 See AHM I , 2023 WL 2825871, at *4 n.9 FDA , 78 F.4th 4th 210 (5th Cir.

FDA 59

FDA Production FDA Approval Regulations 59

Drug & Device Law

DECEMBER 29, 2023

In 2023 there seemed to be an unusually large number of other decisions that are likely to have a substantial impact on what we or our clients do, but involve either different products, non-product claims, or both. In 2023, these include United States ex rel. 2023) (no medical monitoring in Delaware) ( here ); Brown v.

Testimonials 105

Testimonials FDA Drugs Vaccine 105